Frost & Sullivan has named Siemens Healthcare the "2013 North American Interventional Radiology Company of the Year" for its interventional imaging solutions in cardiology, radiology and hybrid surgery. The Frost & Sullivan study states, "Siemens is extremely well positioned within the interventional cardiology segment, within the overarching surgical clinical segment, as well as neurology, oncology and pediatrics." Siemens says it has been able to sustain market expansion momentum by continually leading the industry in the development of new technology for high-end interventional equipment, while enhancing current clinical applications and enabling new ones. Over the last decade, Siemens said it has succeeded in establishing the company as the market and technology leader in the United States by exploring new possibilities to enhance interventional therapy and patient care.

August 22, 2013 – BioVentrix announced the successful first use of its Revivent Myocardial Anchoring System via the Less Invasive Ventricular Enhancement (LIVE) procedure in Germany. The successful procedure was performed on a 54-year-old man suffering from advanced heart failure at the Schön Klinik Vogtareuth in Vogtareuth, Germany.

IMRIS Inc. announced that a craniotomy recently performed on a 5-year-old boy with epilepsy was the 500th neurosurgical case at Cook Children's Medical Center in Fort Worth, Texas, using its intraoperative magnetic resonance imaging (iMRI) system. Cook Children's was the second children's hospital in the United States and fourth hospital worldwide with an IMRIS system that features a high-field MRI, which moves between surgical and diagnostic rooms using ceiling-mounted rails.

Patient enrollment has been initiated in a post-market registry for the Combo Dual Therapy Stent to evaluate its long-term safety and performance in routine clinical practice. The prospective, multicenter, all-comers REMEDEE Registry (Multicenter, Prospective, Clinical Outcomes After Deployment of the Abluminal Sirolimus Coated Bio-Engineered Stent — Combo Bio-Engineered Sirolimus Eluting Stent — Post Market Registry) will enroll 1,000 patients at nine European sites. As of today, more than 100 patients have already been enrolled.